Imatinib mesylate is under clinical development by Inhibikase Therapeutics and currently in Phase I for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia). According to GlobalData, Phase I drugs for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Imatinib mesylate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Imatinib mesylate overview

Imatinib mesylate (IkT-001Pro) is under development for the treatment of chronic myeloid leukemia. It is developed based on RAMP technology. The drug candidate acts by targeting host-directed and Bcr-Abl tyrosine kinase. It was also under development for the prevention of smallpox, Ebola and Marburg infections and Equine encephalitis infections (as a countermeasure against bioterrorism), cancer and polyomaviruses associated nephropathy (PVAN) caused by BK virus and progressive multifocal leukoencephalopathy (PML) caused by John cunningham virus.

Inhibikase Therapeutics overview

Inhibikase Therapeutics is a biotechnology business dedicated to the development and commercialization of small-molecule kinase inhibitor therapeutics for the safe and effective treatment of neurological illnesses both inside and outside the brain. The company is headquartered in Atlanta, Georgia, the US.

For a complete picture of Imatinib mesylate’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.